Fosamax and Osteonecrosis of the Jaw: Scientific Evidence of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health to Specific Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and therapeutic interventions. Within this broad context, discussions of bone health and pharmaceutical treatments have been standard, with bisphosphonates like Fosamax recognized primarily for their role in managing osteoporosis. This established framework provided a baseline for patients and clinicians to weigh benefits against potential side effects, yet it remained largely confined to clinical and lifestyle considerations. Transitioning from this general health perspective, a more focused inquiry emerges when considering the specific exposure pathways associated with Fosamax use. The pivot from a broad informational heritage to an occupational exposure concern requires examining how prolonged or high-dose administration of this medication may intersect with dental and jaw health. In occupational settings, such as those involving healthcare professionals or patients with chronic conditions, the cumulative exposure to bisphosphonates becomes a salient variable. This shift in focus moves beyond general health advice to a targeted assessment of risk factors, particularly the duration and intensity of drug exposure. By reframing the discussion around exposure rather than disease mechanisms, the transition enables a neutral exploration of how routine pharmaceutical use may correlate with adverse outcomes in specific populations, without invoking causal claims.

Bridging to Fosamax and Jaw Health

Building on the general health context, the specific connection between Fosamax (alendronate) and osteonecrosis of the jaw (ONJ) warrants detailed examination. Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its mechanism involves inhibiting bone resorption, which increases bone mass and reduces fracture incidence. However, a serious adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw. Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region. Clinical presentation typically involves areas of exposed bone that persist for more than eight weeks, often accompanied by pain, swelling, infection, and delayed healing after dental procedures. Diagnosis is primarily clinical, based on visual examination and patient history, and may be supported by imaging studies to rule out other conditions. The condition can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Pharmacological Mechanisms and Animal Evidence

The scientific evidence connecting Fosamax to ONJ is supported by multiple lines of investigation. Pharmacologically, bisphosphonates like alendronate accumulate in bone tissue, particularly in areas of high bone turnover such as the jaw. They inhibit osteoclast activity, which can suppress normal bone remodeling and repair. This suppression is thought to impair the jawbone's ability to heal from microdamage or after dental procedures, leading to necrosis. Mechanistic pathways linking Fosamax to ONJ involve altered bone metabolism, reduced blood supply, and increased susceptibility to infection. Multiscale characterization of jawbone in animal models has provided comprehensive information to help understand jawbone-specific responses to bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies using estrogen-deficient rats treated with alendronate have examined effects on jawbone properties, including tissue mineral density distribution and mechanical stability of teeth in the alveolar socket (https://pubmed.ncbi.nlm.nih.gov/40345077/). These investigations contribute to understanding how bisphosphonates may compromise jawbone integrity.

Timeline, Risk Factors, and Clinical Warnings

The timeline between exposure to Fosamax and documented harm varies. The time to onset of symptoms has been reported to range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, a subset of patients experienced recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under Warnings and Precautions. This section states that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and outlines known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also advises that discontinuation of bisphosphonate treatment may reduce the risk for ONJ in patients requiring invasive dental procedures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). These warnings provide healthcare professionals and patients with information to assess and manage the risk.

Causation Considerations for Affected Patients

Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax use and the development of ONJ, as well as the presence of other risk factors. While ONJ can occur spontaneously, its association with bisphosphonate therapy is well-documented. Patients who develop ONJ while on Fosamax should be evaluated for other contributing factors, such as dental procedures, cancer, or concomitant medications. The label notes that most patients had relief of symptoms after stopping the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56), suggesting a causal link in some cases. However, the condition can also occur in patients not taking bisphosphonates, complicating individual causation assessments. In summary, the scientific evidence establishes a connection between Fosamax and osteonecrosis of the jaw through pharmacological mechanisms, clinical reports, and animal studies. The risk is influenced by duration of use, dental procedures, and other patient factors. Warnings in the prescribing information aim to inform clinicians and patients, but individual cases require careful evaluation of causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

The scientific evidence includes pharmacological mechanisms where bisphosphonates like alendronate accumulate in jawbone, inhibit osteoclast activity, and impair bone remodeling. Clinical reports document ONJ in patients taking Fosamax, and animal studies show jawbone-specific effects (https://pubmed.ncbi.nlm.nih.gov/40345077/). The prescribing information also includes warnings about ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What are the risk factors for developing ONJ while on Fosamax?

Risk factors include invasive dental procedures (tooth extraction, implants, boney surgery), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (periodontal disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Duration of bisphosphonate use also increases risk.

How long after starting Fosamax can ONJ occur?

The time to onset of symptoms has been reported to range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, risk may increase with longer duration of exposure.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.